

Date of issue

21.03.07

Company Update

INVESTMENT DATA


Share Price	\$0.68
Issued Capital	
Ordinary Shares	389.6m
Options	9.5m
Fully Diluted	399.1m
Market Capitalisation	\$271.4m
52 Week Low/High	\$0.195 / \$0.73
Valuation	\$1.35

Top 20 shareholders as at 15 Aug 2006 held 64% of total shares on issue.

	Year end Jun 06a	07f	08f	09f
Revenue	\$m 0.7	0.0	0.0	0.0
EBITDA	\$m -11.8	-25.1	-28.6	-28.7
NPAT	\$m -17.8	-24.0	-24.2	-25.2
EPS (adj)	¢ -12.9	-8.3	-6.2	-6.5
EPS growth	% na	na	na	na
PER	x na	na	na	na

Data is normalised and fully diluted.

Share price chart: AVX



Avexa (AVX)

Buy 2

Cashing up to commence phase III

Capital raising of \$75m to fund phase III program

AVX has announced plans to raise \$75.6m to fund its phase III clinical trials program;

- \$15.4m has been raised via a placement to US institutions at an issue price of \$0.53/share
- \$60.2m to be raised via a renounceable rights issue whereby existing shareholders will be offered two new ordinary shares for every five existing shares at an issue price of \$0.53/share

The size of the capital raising is in line with the recent trend in the local biotech sector to raise funds for late-stage drug development. The two most notable raisings have been Pharmaxis' (PXS) \$87m placement in Nov 2005 and Peplin's (PEP) \$40m raise in May 2006.

Impact of changes to earnings estimates softened by lower than expected issue price - valuation downgraded to \$1.35 from \$1.57

The increase to our earnings estimates on 19 Mar 2007 resulted in a valuation upgrade to \$1.57. This was based on an increase to our probability weighting to 85% and peak market share assumption to 25%. In addition, we estimated that AVX would raise \$50m at an issue price of \$0.70/share. Today's capital raising announcement has led us to downgrade our valuation to \$1.35.

Buy 2 rating re-iterated

Despite the valuation downgrade, we re-iterate our 'Buy 2' rating. In its investor road show presentations yesterday, AVX made reference to two important upcoming events we were previously unaware of. We expect these events will drive the price over the next 6 months;

- **Presentation of trial data at IAS (International AIDS Society) conference in July** - AVX will present the full data package for ATC at the fourth IAS conference on HIV Pathogenesis, Treatment and Prevention, to be held in Sydney during July 22 to July 25, 2007. The IAS is the world's leading independent association of HIV/AIDS professionals with its conferences aiming to provide critical platforms for presenting new research, sharing best practice and advancing the fight against HIV/AIDS.
- **Paediatrics trial commencing in 2H 2007 may allow drug launch up to 12 months earlier than expected** - AVX is planning to commence a trial in HIV-infected children during 2H 2007. Although HIV-infected children represent a very niche market (approximately 1m children worldwide are infected with HIV; including 60,000-75,000 children in the US), the regulatory path to approval appears relatively fast compared to registration for use in adults. Our estimates suggest ATC could be approved for use in children by mid 2009. This is based on AVX gaining FDA approval to conduct a trial in approximately 50-100 children and recruiting patients within 12-18 months. AVX is yet to clarify the timelines for this indication but should this plan progress, ATC could be on market at least 6-12 months earlier than expected. Once approved, ATC is likely to be used "off-label" in adults. Our current \$1.35 valuation still assumes market launch in mid 2010 however we will incorporate the earlier launch dates as we receive further clarification from the company.

Linda Ong

■ long@bellpotter.com.au

Company (AVX)					Share price:	\$0.680					
As at	20/03/2007	Recommendation:				BUY 2	Market cap (\$m):				\$271.4m
Income Statement					Valuation Data						
Year end June 30	2006A	2007F	2008F	2009F	Year end June 30	2006A	2007F	2008F	2009F		
Revenue	\$0.74m	\$0.00m	\$0.00m	\$0.00m	Adjusted net profit	-\$17.83m	-\$24.02m	-\$24.20m	-\$25.21m		
EBITDA	-11.78	-25.08	-28.57	-28.68	Adjusted EPS*	-12.9c	-8.3c	-6.2c	-6.5c		
EBITA	-11.83	-25.08	-28.57	-28.68	EPS growth	na	na	na	na		
Amortisation	-6.00	0.00	0.00	0.00	P/E ratio	na	na	na	na		
EBIT	-17.83	-25.08	-28.57	-28.68	OpCFPS (excl. abnormals)	-1.4c	-7.7c	-4.4c	-6.5c		
Interest	0.00	1.06	4.37	3.47	Price/OpCFPS	-47.4x	-8.8x	-15.5x	-10.5x		
Abnormals	0.00	0.00	0.00	0.00	DPS	0.0c	0.0c	0.0c	0.0c		
Pre-tax profit	-17.83	-24.02	-24.20	-25.21	Yield	0.00%	0.00%	0.00%	0.00%		
Tax	0.00	0.00	0.00	0.00	EV/EBITDA	na	na	na	na		
Reported net profit	-17.83	-24.02	-24.20	-25.21	EV/EBITA	na	na	na	na		
Adjusted net profit	-17.83	-24.02	-24.20	-25.21	* FY05 Proforma						
Proforma Adjusted net profit											
(adjusted net profit = pre-tax profit before abnormals and goodwill minus tax at marginal rate)											
Cashflow											
Year end June 30	2006A	2007F	2008F	2009F							
Reconciliation											
Net profit	-\$17.83m	-\$24.02m	-\$24.20m	-\$25.21m							
Amortisation	6.00	0.00	0.00	0.00							
Depreciation	0.05	0.00	0.00	0.00							
Change in working capital	8.94	1.60	7.09	0.00							
Other	0.00	0.00	0.00	0.00							
Net operating cashflow	-2.84	-22.42	-17.11	-25.21							
Investing cashflow											
Sale/purchase of PPE	-0.14	0.00	0.00	0.00							
Payments for businesses	0.00	0.00	0.00	0.00							
Investments & others	0.00	0.00	0.00	0.00							
Proceeds from sale of PPE/other	0.00	0.00	0.00	0.00							
Net investing cash flow	-0.14	0.00	0.00	0.00							
Financing activities											
Issue of shares	14.39	85.43	0.00	0.00							
Buy backs	0.00	0.00	0.00	0.00							
Dividends paid	0.00	0.00	0.00	0.00							
Debt	-0.85	0.00	0.00	0.00							
Others	0.00	0.00	0.00	0.00							
Net financing cash flow	13.54	85.43	0.00	0.00							
Effects of exchange rate changes	0.00	0.00	0.00	0.00							
Net change in cash held	10.55	63.01	-17.11	-25.21							
Balance Sheet											
Year end June 30	2006A	2007F	2008F	2009F							
Assets											
Cash assets	\$20.23m	\$83.24m	\$66.12m	\$40.91m							
Receivables	0.03	0.00	0.00	0.00							
Inventories	0.00	0.00	0.00	0.00							
Other	0.11	0.19	0.46	0.46							
Total current assets	20.37	83.43	66.58	41.37							
Plant and equipment	0.22	0.22	0.22	0.22							
Non-current receivables	0.00	0.00	0.00	0.00							
Intangible assets	0.00	0.00	0.00	0.00							
Other / financial assets	0.00	0.00	0.00	0.00							
Deferred tax assets	0.00	0.00	0.00	0.00							
Total non-current assets	0.22	0.22	0.22	0.22							
Total assets	20.59	83.64	66.80	41.59							
Liabilities											
Short term debt	0.00	0.00	0.00	0.00							
Payables	3.36	4.81	11.50	11.50							
Current tax liabilities	0.00	0.00	0.00	0.00							
Provisions	0.28	0.48	1.15	1.15							
Other liabilities	0.00	0.00	0.00	0.00							
Total current liabilities	3.64	5.29	12.65	12.65							
Long term debt	0.00	0.00	0.00	0.00							
Payables	0.00	0.00	0.00	0.00							
Provisions	0.03	0.03	0.03	0.03							
Total non-current liabilities	0.03	0.03	0.03	0.03							
Total liabilities	3.67	5.32	12.68	12.68							
Net assets	16.92	78.33	54.12	28.91							
Equity											
Contributed equity	48.16	133.59	133.59	133.59							
Reserves & outside equity	0.00	0.00	0.00	0.00							
Retained earnings	-31.24	-55.27	-79.47	-104.68							
Total equity	16.92	78.33	54.12	28.91							
Diluted shares on issue	197.85	389.63	389.63	389.63							
Weighted ave diluted shares	197.85	290.34	389.63	389.63							

BELL POTTER OFFICES

www.bellpotter.com.au

info@bellpotter.com.au

TOLL FREE 133 788

ABN 25 006 390 772

AFS Licence No. 243480

ADELAIDE

LEVEL 6, DA COSTA BUILDING
68 GRENFELL STREET
ADELAIDE SA 5000
TEL: 08 8224 2722
FAX: 08 8224 2799

BRISBANE

LEVEL 17, 10 EAGLE STREET
BRISBANE QLD 4000
TEL: 07 3295 2600
FAX: 07 3295 2688

CAIRNS

CNR SPENCE & GRAFTON STREETS
CAIRNS QLD 4870
TEL: 07 4047 4188
FAX: 07 4047 4199

GEELONG

LEVEL 1, 122 YARRA STREET
GEELONG VIC 3220
TEL: 03 5227 7000
FAX: 03 5227 7099

GOLD COAST

LEVEL 8, 50 CAVILL AVENUE
SURFERS PARADISE QLD 4217
TEL: 07 5554 4333
FAX: 07 5554 4399

HOBART

LEVEL 9, AMP BUILDING
86 COLLINS STREET
HOBART TAS 7000
TEL: 03 6231 1677
FAX: 03 6231 3744

MACKAY

CITY COURT, 78 VICTORIA STREET
MACKAY QLD 4740
TEL: 07 4957 6996
FAX: 07 4951 4114

MELBOURNE

LEVEL 29, 101 COLLINS STREET
MELBOURNE VIC 3000
TEL: 03 9256 8700
FAX: 03 9256 8787

MORNINGTON

SUITE 1, 330 MAIN STREET
MORNINGTON VIC 3931
TEL: 03 5970 0101
FAX: 03 5970 0199

PERTH

LEVEL 37, EXCHANGE PLAZA
2 THE ESPLANADE
PERTH WA 6000
TEL: 08 9326 7666
FAX: 08 9326 7676

SYDNEY

LEVEL 33, 225 GEORGE STREET
SYDNEY NSW 2000
TEL: 02 9255 7200
FAX: 02 9255 7227

TOOWOOMBA

3 DUGGAN STREET
TOOWOOMBA QLD 4350
TEL: 07 4638 5988
FAX: 07 4639 2608

Important Disclaimer—This may affect your legal rights: Because this document has been prepared without consideration of any specific client's financial situation, particular needs and investment objectives, a Bell Potter Securities Limited investment adviser (or the financial services licensee, or the proper authority of such licensee, who has provided you with this report by arrangement with Bell Potter Securities Limited) should be consulted before any investment decision is made. While this document is based on the information from sources which are considered reliable, Bell Potter Securities Limited, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does Bell Potter Securities Limited accept any responsibility to inform you of any matter that subsequently comes to its notice, which may affect any of the information contained in this document. This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of Bell Potter Securities Limited. This is general investment advice only and does not constitute advice to any person.

Disclosure of Interest: Bell Potter Securities Limited receives commission from dealing in securities and its authorised representatives, or introducers of business, may directly share in this commission. Bell Potter Securities and its associates may hold shares in the companies recommended.